Back to Montana

SB211 • 2025

Revise emergency use of epinephrine in school setting to include nasal spray

Revise emergency use of epinephrine in school setting to include nasal spray

Education
Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor
Cora Neumann
Last action
2025-04-17
Official status
Chapter Number Assigned
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Revise emergency use of epinephrine in school setting to include nasal spray

Revise emergency use of epinephrine in school setting to include nasal spray

What This Bill Does

  • Revise emergency use of epinephrine in school setting to include nasal spray

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2025-04-17 SENATE

    Chapter Number Assigned

  2. 2025-04-16 SENATE

    (S) Signed by Governor

  3. 2025-04-08 SENATE

    (S) Transmitted to Governor

  4. 2025-04-07 HOUSE

    (H) Signed by Speaker

  5. 2025-04-01 SENATE

    (S) Signed by President

  6. 2025-03-28 SENATE

    (S) Returned from Enrolling

  7. 2025-03-26 HOUSE

    (H) Scheduled for 3rd Reading

  8. 2025-03-26 HOUSE

    (H) 3rd Reading Concurred

  9. 2025-03-26 SENATE

    (S) Sent to Enrolling

  10. 2025-03-25 HOUSE

    (H) Scheduled for 2nd Reading

  11. 2025-03-25 HOUSE

    (H) 2nd Reading Concurred

  12. 2025-03-19 HOUSE

    (H) Committee Report--Bill Concurred

  13. 2025-03-18 HOUSE

    (H) Committee Executive Action--Bill Concurred

  14. 2025-03-05 HOUSE

    (H) Hearing

  15. 2025-02-13 SENATE

    (S) Transmitted to House

  16. 2025-02-13 HOUSE

    (H) Referred to Committee

  17. 2025-02-13 HOUSE

    (H) First Reading

  18. 2025-02-12 SENATE

    (S) Scheduled for 3rd Reading

  19. 2025-02-12 SENATE

    (S) 3rd Reading Passed

  20. 2025-02-11 SENATE

    (S) Scheduled for 2nd Reading

  21. 2025-02-11 SENATE

    (S) 2nd Reading Passed

  22. 2025-02-06 SENATE

    (S) Committee Report--Bill Passed

  23. 2025-02-05 SENATE

    (S) Committee Executive Action--Bill Passed

  24. 2025-01-31 SENATE

    (S) Sponsor List Modified

  25. 2025-01-30 SENATE

    (S) Hearing

  26. 2025-01-27 SENATE

    (S) First Reading

  27. 2025-01-27 SENATE

    (S) Referred to Committee

  28. 2025-01-24 SENATE

    (S) Introduced

  29. 2025-01-23 HOUSE

    (LC) Draft Delivered to Requester

  30. 2025-01-16 HOUSE

    (LC) Draft in Assembly

  31. 2025-01-16 HOUSE

    (LC) Draft Ready for Delivery

  32. 2025-01-14 HOUSE

    (LC) Draft in Edit

  33. 2025-01-14 HOUSE

    (LC) Draft in Input/Proofing

  34. 2025-01-14 HOUSE

    (LC) Draft in Final Drafter Review

  35. 2025-01-13 HOUSE

    (LC) Draft in Legal Review

  36. 2024-11-14 HOUSE

    (LC) Drafter Assigned

Official Summary Text

Revise emergency use of epinephrine in school setting to include nasal spray

Current Bill Text

Read the full stored bill text
****
69th Legislature 2025 SB 211
- 1 - Authorized Print Version – SB 211
ENROLLED BILL
AN ACT REVISING THE EMERGENCY USE OF EPINEPHRINE IN A SCHOOL SETTING TO INCLUDE
NASAL SPRAY; AMENDING SECTIONS 20-5-420 AND 20-5-421, MCA; AND PROVIDING AN IMMEDIATE
EFFECTIVE DATE.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
Section 1. Section 20-5-420, MCA, is amended to read:
"20-5-420. Self-administration or possession of asthma, severe allergy, or anaphylaxis
medication. (1) As used in 20-5-421 and this section, the following definitions apply:
(a) "Anaphylaxis" means a systemic allergic reaction that can be fatal in a short time period and is
also known as anaphylactic shock.
(b) "Asthma" means a chronic disorder or condition of the lungs that requires lifetime, ongoing
medical intervention.
(c) "Medication" means a medicine, including inhaled bronchodilators, inhaled corticosteroids, and
autoinjectable epinephrine, and epinephrine nasal spray, prescribed by a licensed physician as defined in 37-3-
102, a physician assistant who has been authorized to prescribe medications as provided in 37-20-404, or an
advanced practice registered nurse with prescriptive authority as provided in 37-8-202(1)(h).
(d) "Self-administration" means a pupil's discretionary use of the medication prescribed for the
pupil.
(e) "Severe allergies" means a life-threatening hypersensitivity to a specific substance such as
food, pollen, or dust.
(2) A school, whether public or nonpublic, shall permit the possession or self-administration of
medication, as prescribed, by a pupil with asthma, severe allergies, or anaphylaxis if the parents or guardians
of the pupil provide to the school:
****
69th Legislature 2025 SB 211
- 2 - Authorized Print Version – SB 211
ENROLLED BILL
(a) written authorization, acknowledging and agreeing to the liability provisions in subsection (4),
for the possession or self-administration of medication as prescribed;
(b) a written statement from the pupil's physician, physician assistant, or advanced practice
registered nurse containing the following information:
(i) the name and purpose of the medication;
(ii) the prescribed dosage; and
(iii) the time or times at which or the special circumstances under which the medication is to be
administered as prescribed;
(c) documentation that the pupil has demonstrated to the health care practitioner and the school
nurse, if available, the skill level necessary to self-administer the asthma, severe allergy, or anaphylaxis
medication as prescribed; and
(d) documentation that the pupil's physician, physician assistant, or advanced practice registered
nurse has formulated a written treatment plan for managing asthma, severe allergies, or anaphylaxis episodes
of the pupil and for medication use, as prescribed, by the pupil during school hours.
(3) The information provided by the parents or guardians must be kept on file in the office of the
school nurse or, in the absence of a school nurse, the school's administrator.
(4) The school district or nonpublic school and its employees and agents are not liable as a result
of any injury arising from the self-administration of medication by the pupil unless an act or omission is the
result of gross negligence, willful and wanton conduct, or an intentional tort. The parents or guardians of the
pupil must be given a written notice and sign a statement acknowledging that the school district or nonpublic
school may not incur liability as a result of any injury arising from the self-administration of medication by the
pupil and that the parents or guardians shall indemnify and hold harmless the school district or nonpublic school
and its employees and agents against any claims, except a claim based on an act or omission that is the result
of gross negligence, willful or wanton misconduct, or an intentional tort.
(5) The permission for self-administration of asthma, severe allergy, or anaphylaxis medication is
effective for the school year for which it is granted and must be renewed each subsequent school year or, if the
medication expires or the dosage, frequency of administration, or other conditions change, upon fulfillment of
the requirements of this section.
****
69th Legislature 2025 SB 211
- 3 - Authorized Print Version – SB 211
ENROLLED BILL
(6) If the requirements of this section are fulfilled, a pupil with asthma, severe allergies, or
anaphylaxis may possess and use the pupil's medication as prescribed:
(a) while in school;
(b) while at a school-sponsored activity;
(c) while under the supervision of school personnel;
(d) before or after normal school activities, such as while in before-school or after-school care on
school-operated property; or
(e) while in transit to or from school or school-sponsored activities.
(7) If provided by the parent, an individual who has executed a caretaker relative educational
authorization affidavit pursuant to 20-5-503, an individual who has executed a caretaker relative medical
authorization affidavit pursuant to 40-6-502, or a guardian and in accordance with documents provided by the
pupil's physician, physician assistant, or advanced practice registered nurse, asthma, severe allergy, or
anaphylaxis medication may be kept by the pupil and backup medication must be kept at a pupil's school in a
predetermined location or locations to which the pupil has access in the event of an asthma, severe allergy, or
anaphylaxis emergency.
(8) Immediately after using epinephrine during school hours, a student shall report to the school
nurse or other adult at the school who shall provide followup care, including making a 9-1-1 emergency call.
(9) Youth correctional facilities are exempt from this section and shall adopt policies related to
access and use of asthma, severe allergy, or anaphylaxis medications."
Section 2. Section 20-5-421, MCA, is amended to read:
"20-5-421. Emergency use of epinephrine in school setting. A school, whether public or
nonpublic, may maintain a stock supply of autoinjectable epinephrine or epinephrine nasal spray to be
administered by a school nurse or other authorized personnel to any student or nonstudent as needed for
actual or perceived anaphylaxis. A school that intends to obtain an order for emergency use of epinephrine in a
school setting or at related activities shall adhere to the following requirements:
(1) A school that stocks an epinephrine autoinjector or nasal spray shall develop a protocol related
to the training of school employees, the maintenance and location of the epinephrine autoinjector or nasal
****
69th Legislature 2025 SB 211
- 4 - Authorized Print Version – SB 211
ENROLLED BILL
spray, and immediate and long-term followup to the administration of the medication, including making a 9-1-1
emergency call.
(2) The epinephrine autoinjector or nasal spray must be prescribed by a physician, advanced
practice registered nurse, or physician assistant. The school must be designated as the patient, and each
prescription for an epinephrine autoinjector or nasal spray must be filled by a licensed pharmacy.
(3) The school shall provide training to authorized personnel. The training must include causes of
anaphylaxis, recognition of signs and symptoms of anaphylaxis, indications for the administration of
epinephrine, the administration technique, and the need for immediate access to a certified emergency
responder. Training must be provided by a school nurse, certified emergency responder, or other health care
professional.
(4) The epinephrine autoinjector or nasal spray must be kept in a secure and easily accessible
location.
(5) A school nurse or other authorized personnel may, in good faith, administer the epinephrine to
any student or nonstudent who is experiencing a potential life-threatening anaphylactic reaction based on the
protocol developed by the school.
(6) If a school stocks an epinephrine autoinjector or nasal spray that has been prescribed to the
school, that school shall inform parents or guardians about the potential use of the epinephrine autoinjector or
nasal spray in an anaphylactic emergency. The school shall make the protocol available upon request.
(7) In accordance with the provisions of 27-1-714, a school district or nonpublic school and its
employees and agents are not liable as a result of any injury arising from the administration of epinephrine to a
student or nonstudent unless an act or omission is the result of gross negligence, willful or wanton misconduct,
or an intentional tort."
Section 3. Effective date. [This act] is effective on passage and approval.
- END -
I hereby certify that the within bill,
SB 211, originated in the Senate.
___________________________________________
Secretary of the Senate
___________________________________________
President of the Senate
Signed this _______________________________day
of____________________________________, 2025.
___________________________________________
Speaker of the House
Signed this _______________________________day
of____________________________________, 2025.
SENATE BILL NO. 211
INTRODUCED BY C. NEUMANN, V. RICCI, S. NOVAK, L. MUSZKIEWICZ, B. EDWARDS, J. ISALY, M. LEE,
M. NIKOLAKAKOS, B. CLOSE, G. OVERSTREET, A. GRIFFITH, M. CUNNINGHAM, T. MANZELLA, W.
CURDY, M. DUNWELL, E. MATTHEWS, W. MCKAMEY, F. SMITH, D. FERN, D. HARVEY, M. REGIER, L.
SMITH, M. YAKAWICH, C. GLIMM, E. BOLDMAN, J. COHENOUR, P. FLOWERS, T. FRANCE, D. HAWK, D.
HAYMAN, J. KARLEN, C. KEOGH, K. KORTUM, F. MANDEVILLE, T. MCGILLVRAY, G. NIKOLAKAKOS, S.
MORIGEAU, A. OLSEN, C. POPE, M. THANE, P. TUSS, M. MARLER, K. BOGNER, D. JOY, J. ETCHART
AN ACT REVISING THE EMERGENCY USE OF EPINEPHRINE IN A SCHOOL SETTING TO INCLUDE NASAL
SPRAY; AMENDING SECTIONS 20-5-420 AND 20-5-421, MCA; AND PROVIDING AN IMMEDIATE
EFFECTIVE DATE.